Enovis Remains on Target for 2022 Growth Goals

Enovis reported 2Q22 orthopedic sales of $147.2 million, +39.9% vs. 2Q21.

While incremental revenue from acquisitions contributed the majority of the company's second-quarter growth, Enovis still drove above-market organic growth of 5.7%. That puts the company on track to achieve the mid-point of its previously given organic growth...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us